|Bid||2.33 x 0|
|Ask||2.39 x 0|
|Day's Range||2.21 - 2.40|
|52 Week Range||1.05 - 2.92|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 13, 2017 - Nov 17, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.69|
The Zacks Analyst Blog Highlights: Halozyme Therapeutics, Protagonist Therapeutics, Aptose Biosciences and Pieris Pharmaceuticals
PORTLAND, Ore. and SAN DIEGO, Dec. 11, 2017-- The OHSU Knight Cancer Institute and Aptose Biosciences Inc. today announced the presentation of preclinical data demonstrating that CG’ 806, a pan-FLT3/pan-BTK ...
SAN DIEGO and TORONTO, Dec. 11, 2017-- Aptose Biosciences Inc. today announced the presentation of preclinical data from research led by The University of Texas MD Anderson Cancer Center demonstrating ...
SAN DIEGO and TORONTO, Nov. 14, 2017-- Aptose Biosciences Inc., a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced financial ...
NEW YORK, NY / ACCESSWIRE / November 14, 2017 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...